Somite.ai

Somite.ai

Somite.ai is building the OpenAI of cellular biology. Their initial focus is to build AI foundation models to produce human tissue for cell therapies. With their proprietary “digital twins of the embryo” and differentiation protocols, Somite addresses current cell therapy limitations - illusive cell lineages, purity, scale, and cost, with ML-guided models to make cell replacement therapies a reality.

Somite is leveraging over 12 years of work at HMS, has compelling pre-clinical data, and owns the seminal patents in the space. To date, they are the only company to efficiently produce human somite-derived cells in vitro. Somite has the potential to cure a wide range of diseases that involve the loss or deficiency of cell populations, such as Diabetes, Obesity, and Muscular Dystrophies.

www.somite.ai

In The News

10.4.2024

This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market

Five scientists walked into a lab late last year and decided to establish a startup combining their wide-ranging expertise, practical experience and breakthrough innovations. The goal of their startup, Somite.ai, is to improve the lives of millions of people by leveraging AI to produce human tissue for cell therapies. The market for the therapies for the diseases they aim to address is estimated at $250 billion.
Read More
10.4.2024

This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market

Five scientists walked into a lab late last year and decided to establish a startup combining their wide-ranging expertise, practical experience and breakthrough innovations. The goal of their startup, Somite.ai, is to improve the lives of millions of people by leveraging AI to produce human tissue for cell therapies. The market for the therapies for the diseases they aim to address is estimated at $250 billion.
Read More